Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICON study of iberdomide + cyclophosphamide + dexamethasone in relapsed/refractory multiple myeloma
NL-OMON54066Phase 2Recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Feb 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iberdomide, cyclophosphamide and dexamethasone in multiple myeloma (MM), sponsored by Vrije University Medical Center. Primary endpoint: Progression-free survival. Started Feb 2021; status: recruiting.
02
Drugs
iberdomidecyclophosphamidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON54066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54066.